
    
      Quikin CD19-CART is a kind of chimeric antigen T cell targeting CD19 with both CD19-CAR gene
      integration and also PD1 knockout by one-step gene-editing. After completion of study
      treatment, subject participation for this study will be followed up to 15 years after
      completion of study treatment.
    
  